^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Selective serotonin reuptake inhibitor

    Related drugs:
    3d
    Efficacy and Safety of Sertraline Combined With Lactobacillus Crispatus in Adolescents With Depression (clinicaltrials.gov)
    P2, N=60, Recruiting, First Affiliated Hospital of Chongqing Medical University | Not yet recruiting --> Recruiting
    Enrollment open
    6d
    Citalopram enhances cisplatin-induced cytotoxicity in T24 bladder cancer cells: An in vitro study. (PubMed, Exp Mol Pathol)
    Citalopram has been shown to improve the efficacy of cisplatin in suppressing T24 bladder cancer cells in vitro.
    Preclinical • Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • MMP2 (Matrix metallopeptidase 2) • BAX (BCL2-associated X protein) • VEGFC (Vascular Endothelial Growth Factor C) • CDH2 (Cadherin 2) • MMP9 (Matrix metallopeptidase 9) • SNAI1 (Snail Family Transcriptional Repressor 1) • SLC2A1 (Solute Carrier Family 2 Member 1)
    |
    cisplatin
    7d
    Sertraline Combined With Multi-Strain Probiotics for Adolescent Depression (clinicaltrials.gov)
    P2, N=120, Recruiting, First Affiliated Hospital of Chongqing Medical University
    New P2 trial
    10d
    ESPRIT: sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19 (clinicaltrials.gov)
    P3, N=160, Recruiting, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Not yet recruiting --> Recruiting | Initiation date: Mar 2026 --> Jun 2026 | Trial primary completion date: Mar 2027 --> Dec 2027
    Enrollment open • Trial initiation date • Trial primary completion date
    10d
    A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD (clinicaltrials.gov)
    P4, N=304, Active, not recruiting, University of Pennsylvania | Trial completion date: Jul 2026 --> Nov 2026 | Trial primary completion date: Jul 2026 --> Nov 2026
    Trial completion date • Trial primary completion date
    11d
    Pupillometry in Delayed Sleep Wake Phase Disorder (clinicaltrials.gov)
    P=N/A, N=220, Recruiting, Northwestern University | Trial primary completion date: Feb 2029 --> Jul 2029
    Trial primary completion date
    13d
    A SMART Approach to Evaluating the Benefits of Common Prescription and OTC Medications for Insomnia (clinicaltrials.gov)
    P4, N=1200, Recruiting, University of Pennsylvania | Not yet recruiting --> Recruiting
    Enrollment open
    13d
    Department of Defense PTSD Adaptive Platform Trial - Master Protocol (clinicaltrials.gov)
    P2, N=800, Recruiting, Global Coalition for Adaptive Research | Trial completion date: Sep 2026 --> Jul 2029 | Trial primary completion date: Mar 2026 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    fluoxetine
    14d
    Mindfulness and Biofeedback for Anxiety Disorders (clinicaltrials.gov)
    P4, N=188, Completed, I.M. Sechenov First Moscow State Medical University
    New P4 trial
    14d
    Fluvoxamine and lycopene alleviate cisplatin-induced kidney fibrosis by modulating miR-21 and fibrotic signaling pathways. (PubMed, Sci Rep)
    FLV and LYC effectively attenuated Cis-induced kidney fibrosis through antioxidant, antiapoptotic, and antifibrotic mechanisms. These findings may provide a new therapeutic approach to counter Cis-induced nephrotoxicity in clinical settings.
    Journal • IO biomarker
    |
    SMAD4 (SMAD family member 4) • MIR21 (MicroRNA 21) • BAX (BCL2-associated X protein) • TGFB1 (Transforming Growth Factor Beta 1) • SMAD3 (SMAD Family Member 3)
    |
    cisplatin
    17d
    TPM-like manipulations exerted an antidepressant effect and regulated amino acid metabolism and GHR/IGF-1 pathway in the liver in adolescent female CUMS rats. (PubMed, Front Physiol)
    Female Sprague-Dawley rats (3-4 weeks) were randomly divided into four groups (n=7-8): control (CON), chronic unpredictable mild stress (CUMS), CUMS + TPM-like manipulations (TPM), and CUMS + fluoxetine (FLX)...TPM-like manipulations prevented CUMS-induced depressive-like behaviors, increased concentration of L-Aspartic Acid, increased the expressions of GHR and IGF-1 in the liver, increased the expressions of IGF-1 and IGF-1R, and inhibited inflammation in the hippocampus in adolescent female rats. However, further study is warranted to draw confirmative results related to liver-brain axis.
    Preclinical • Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • IGF1 (Insulin-like growth factor 1) • IL1B (Interleukin 1, beta)
    |
    fluoxetine
    27d
    Identifying and Treating Depression in the Orthopaedic Trauma Population (clinicaltrials.gov)
    P4, N=100, Recruiting, Wake Forest University Health Sciences | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    fluoxetine